NASDAQ$AXSM
Axsome Therapeutics Inc · Q4 2023 earnings
Q4 2023 earnings · · Investor relations
Briefing
Axsome reported fourth quarter and full year 2023 financial results and provided a business update.
Axsome Therapeutics reported a transformational year in 2023, marked by successful commercial execution and substantial pipeline advancement. Total net product revenues for Q4 2023 were $71.5 million, a 193% increase year-over-year, driven by Auvelity and Sunosi sales. The company is advancing its pipeline with multiple Phase 3 trials and anticipates NDA submissions for AXS-07 and AXS-14 in the first half of 2024.
- Total net product revenues reached $71.5 million in Q4 2023, representing a 193% year-over-year growth.
- Auvelity net product sales were $49.0 million in Q4 2023, its first full year of launch.
- Sunosi net product revenues were $22.5 million in Q4 2023, a 17% increase year-over-year.
- The company anticipates NDA submissions for AXS-07 in migraine and AXS-14 in fibromyalgia in the first half of 2024.
Headline financials
Revenue & EPS history
Axsome · Revenue · Quarterly
$71.5M
Revenue by segment
Axsome · $57.8M total across 2 segments · Q3 2023
- AUVELITY$37.7M—65.2%
- SUNOSI$20.1M+19.6%34.8%
Forward guidance
Axsome anticipates continued momentum in 2024, focusing on driving growth for Auvelity and Sunosi, potential NDA submissions for migraine and fibromyalgia, and Phase 3 trial readouts in narcolepsy, Alzheimer's disease agitation, and ADHD. The company also plans to initiate new pivotal trials in depression, binge eating disorder, and shift work disorder.
Tailwinds
- NDA resubmission for AXS-07 for migraine is expected in 1H 2024.
- NDA submission for AXS-14 for fibromyalgia is expected in 1H 2024.
- Topline results from the Phase 3 SYMPHONY trial of AXS-12 in narcolepsy are anticipated in 1Q 2024.
- Phase 3 trials of solriamfetol in major depressive disorder, binge eating disorder, and shift work disorder are expected to be initiated in 1Q 2024.
- Topline results from the Phase 3 ADVANCE-2 trial of AXS-05 for Alzheimer’s disease agitation and the Phase 3 FOCUS trial of solriamfetol in ADHD are expected in 2H 2024.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q4 2023
-1.0%
Avg return
Earnings day
-2.9%
Avg return
5 days after
+1.7%
Avg return
30 days after
51%
21 / 41 earnings
Positive
+12.9%
Q1 2022
Best reaction
-53.5%
Q2 2021
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | +8.1% | +5.3% | +13.0% | |
| Q4 2025 | -4.7% | -10.8% | -11.9% | |
| Q3 2025 | +1.9% | +2.3% | +9.5% | |
| Q1 2025 | +3.7% | -4.0% | -3.6% | |
| Q4 2024 | -2.3% | +5.0% | -3.7% | |
| Q3 2024 | +7.5% | +2.4% | +3.7% | |
| Q2 2024 | +1.3% | -1.6% | +13.2% | |
| Q1 2024 | +2.9% | -3.1% | -0.9% | |
| Q4 2023 | -11.5% | -14.9% | -12.9% | |
| Q3 2023 | -3.1% | -11.9% | +6.5% | |
| Q2 2023 | -1.5% | -5.5% | +10.7% | |
| Q1 2023 | +4.1% | +7.1% | +2.4% | |
| Q4 2022 | +11.7% | +6.9% | +2.3% | |
| Q3 2022 | +11.2% | +3.4% | +36.9% | |
| Q2 2022 | +11.7% | +6.8% | +41.3% | |
| Q1 2022 | +12.9% | -6.1% | -24.3% | |
| Q4 2021 | +11.9% | +6.4% | +47.2% | |
| Q3 2021 | +1.4% | -2.3% | -12.6% | |
| Q2 2021 | -53.5% | -55.3% | -48.9% | |
| Q1 2021 | +0.1% | +2.6% | +11.5% | |
| Q4 2020 | +3.6% | -3.5% | -15.9% | |
| Q3 2020 | -9.7% | -6.3% | +7.1% | |
| Q2 2020 | -0.6% | +1.2% | -7.3% | |
| Q1 2020 | -2.8% | -7.9% | -15.7% | |
| Q4 2019 | -16.8% | -38.7% | -23.8% | |
| Q3 2019 | -1.2% | -4.6% | +76.4% | |
| Q2 2019 | +2.2% | +11.0% | -0.5% | |
| Q1 2019 | +7.2% | +10.7% | +12.2% | |
| Q4 2018 | +4.6% | +24.3% | +29.2% | |
| Q3 2018 | -15.8% | -28.1% | -24.7% | |
| Q2 2018 | -1.9% | -8.6% | +27.6% | |
| Q1 2018 | +1.5% | +3.0% | +4.5% | |
| Q4 2017 | +2.6% | +6.5% | -8.4% | |
| Q3 2017 | -4.1% | +1.0% | -0.5% | |
| Q2 2017 | -5.0% | -12.6% | -19.3% | |
| Q1 2017 | -1.2% | -1.2% | -4.8% | |
| Q4 2016 | -4.1% | +6.1% | -27.6% | |
| Q3 2016 | +0.7% | +4.1% | -17.8% | |
| Q2 2016 | -1.4% | -3.4% | -1.6% | |
| Q1 2016 | -1.4% | -3.4% | -1.6% | |
| Q4 2015 | -10.0% | — | — | |
| Q3 2015 | — | — | — | |
| Q2 2015 | — | — | — | |
| Q1 2015 | — | — | — | |
| Q4 2014 | — | — | — | |
| Q3 2014 | — | — | — | |
| Q2 2014 | — | — | — | |
| Q1 2014 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro